207 results on '"Rovira, Ana"'
Search Results
202. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer.
- Author
-
Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, and Gomis RR
- Subjects
- Adult, Aged, Animals, Biomarkers, Tumor genetics, Bone Neoplasms genetics, Bone Neoplasms pathology, Bone Neoplasms secondary, Breast Neoplasms pathology, Cell Differentiation genetics, Chromatin genetics, Female, Gene Expression Regulation, Neoplastic, Genome, Human genetics, Humans, Mice, Middle Aged, Neoplasm Metastasis, Prognosis, RNA, Small Interfering genetics, Receptors, Estrogen genetics, Xenograft Model Antitumor Assays, Breast Neoplasms genetics, GATA3 Transcription Factor genetics, Hepatocyte Nuclear Factor 3-alpha genetics, Ribosomal Protein S6 Kinases, 90-kDa genetics
- Abstract
For many patients with breast cancer, symptomatic bone metastases appear after years of latency. How micrometastatic lesions remain dormant and undetectable before initiating colonization is unclear. Here, we describe a mechanism involved in bone metastatic latency of oestrogen receptor-positive (ER
+ ) breast cancer. Using an in vivo genome-wide short hairpin RNA screening, we identified the kinase MSK1 as an important regulator of metastatic dormancy in breast cancer. In patients with ER+ breast cancer, low MSK1 expression associates with early metastasis. We show that MSK1 downregulation impairs the differentiation of breast cancer cells, increasing their bone homing and growth capacities. MSK1 controls the expression of genes required for luminal cell differentiation, including the GATA3 and FOXA1 transcription factors, by modulating their promoter chromatin status. Our results indicate that MSK1 prevents metastatic progression of ER+ breast cancer, suggesting that stratifying patients with breast cancer as high or low risk for early relapse based on MSK1 expression could improve prognosis.- Published
- 2018
- Full Text
- View/download PDF
203. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.
- Author
-
Zazo S, González-Alonso P, Martín-Aparicio E, Chamizo C, Cristóbal I, Arpí O, Rovira A, Albanell J, Eroles P, Lluch A, Madoz-Gúrpide J, and Rojo F
- Abstract
Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to trastuzumab at diagnosis, and most patients with metastatic disease that initially respond to trastuzumab eventually progress (acquired resistance). Consequently, there is an urgent need to improve our knowledge of the mechanisms governing resistance, so that specific therapeutic strategies can be developed to provide improved efficacy. We generated new cell lines derived from BCCL through extended exposure to trastuzumab. Drug-conditioned populations were authenticated for their molecular profile and their resistance rate was determined. Heterogeneous HER2 amplification was observed across most of the BCCLs, ranging from cells without HER2 amplification to elevated HER2 gene copy numbers in others. Using a phospho-antibody array we analyzed the status of kinase receptors and effectors from different cellular pathways. This revealed that HER2, AKT, and S6RP presented high phosphorylation levels with specific variations between sensitive and resistant populations. In addition, differences in phosphorylation levels for several of those pathways targets were found between sensitive and resistant lines. Furthermore, a biochemical study characterized patterns of molecular alterations similar to those commonly described in breast cancer. Finally, a subcutaneous xenograft murine model confirmed the resistance to trastuzumab of the established cell line. We conclude that these resistant BCCLs can be a valuable tool to gain insight into the mechanisms of acquisition of trastuzumab resistance.
- Published
- 2016
204. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
- Author
-
Dalmases A, González I, Menendez S, Arpí O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, and Rojo F
- Subjects
- Animals, Apoptosis drug effects, Apoptosis genetics, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cell Line, Tumor, Female, Gene Expression Regulation, Neoplastic drug effects, HEK293 Cells, Humans, MCF-7 Cells, Mice, NF-kappa B metabolism, Prognosis, Signal Transduction drug effects, Transcriptional Activation drug effects, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Antibiotics, Antineoplastic pharmacology, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Doxorubicin pharmacology, NF-kappa B genetics, Tumor Suppressor Protein p53 deficiency
- Abstract
NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional relevance at transcriptional level on NF-кB-dependent genes and the biological consequences are unclear. We studied NF-кB-dependent gene expression induced by doxorubicin in breast cancer cells and fresh human cancer specimens with different genetic backgrounds focusing on their p53 status. NF-кB-dependent signature of doxorubicin was identified by gene expression microarrays in breast cancer cells treated with doxorubicin and the IKKβ-inhibitor MLN120B, and confirmed ex vivo in human cancer samples. The association with p53 was functionally validated. Finally, NF-кB activation and p53 status was determined in a cohort of breast cancer patients treated with adjuvant doxorubicin-based chemotherapy. Doxorubicin treatment in the p53-mutated MDA-MB-231 cells resulted in NF-кB driven-gene transcription signature. Modulation of genes related with invasion, metastasis and chemoresistance (ICAM-1, CXCL1, TNFAIP3, IL8) were confirmed in additional doxorubicin-treated cell lines and fresh primary human breast tumors. In both systems, p53-deficient background correlated with the activation of the NF-кB-dependent signature. Furthermore, restoration of p53WT in the mutant p53 MDA-MB-231 cells impaired NF-кB driven transcription induced by doxorubicin. Moreover, a p53 deficient background and nuclear NF-кB/p65 in breast cancer patients correlated with reduced disease free-survival. This study supports that p53 deficiency is necessary for a doxorubicin driven NF-кB-response that limits doxorubicin cytotoxicity in breast cancer and is linked to an aggressive clinical behavior.
- Published
- 2014
- Full Text
- View/download PDF
205. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
- Author
-
Dalmases A, Rojo F, Rovira A, and Albanell J
- Subjects
- Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents pharmacology, Breast Neoplasms drug therapy, Breast Neoplasms enzymology, Breast Neoplasms genetics, Cetuximab, Drug Resistance, Neoplasm, ErbB Receptors immunology, ErbB Receptors physiology, Female, Humans, Lapatinib, Neoplasm Proteins immunology, Neoplasm Proteins physiology, Neoplasms enzymology, Neoplasms genetics, Panitumumab, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Quinazolines pharmacology, Quinazolines therapeutic use, Receptor, ErbB-2 immunology, Receptor, ErbB-2 physiology, Research Design, Signal Transduction drug effects, Translational Research, Biomedical, Trastuzumab, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Clinical Trials as Topic methods, ErbB Receptors antagonists & inhibitors, Medical Oncology methods, Molecular Targeted Therapy, Neoplasm Proteins antagonists & inhibitors, Neoplasms drug therapy, Receptor, ErbB-2 antagonists & inhibitors
- Published
- 2013
- Full Text
- View/download PDF
206. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
- Author
-
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, and Mellado B
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms drug therapy, Cell Survival, Disease Progression, Docetaxel, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drug Synergism, Heterocyclic Compounds, 3-Ring pharmacology, Humans, Interleukin-6 biosynthesis, Interleukin-6 blood, Lymph Nodes, Male, Middle Aged, NF-kappa B metabolism, Neoplasm Metastasis drug therapy, Prognosis, Prostate-Specific Antigen analysis, Prostatic Neoplasms mortality, Prostatic Neoplasms secondary, Pyridines pharmacology, Statistics as Topic, Survival Analysis, Tumor Cells, Cultured, Drug Resistance, Neoplasm physiology, Heterocyclic Compounds, 3-Ring therapeutic use, Interleukin-6 physiology, NF-kappa B antagonists & inhibitors, Prostatic Neoplasms drug therapy, Pyridines therapeutic use, Taxoids therapeutic use
- Abstract
Purpose: To investigate whether nuclear factor kappaB (NF-kappaB)/interleukin 6 (IL-6) was linked to docetaxel response in human prostate cancer cell lines, and whether inhibition of NF-kappaB sensitized tumor cells to docetaxel. We also aimed to correlate IL-6 (as a surrogate marker of NF-kappaB) and docetaxel response in hormone-independent prostate cancer (HIPC) patients., Experimental Design: Hormone-dependent (LNCaP) and hormone-independent (PC-3 and DU-145) prostate cancer cell lines were exposed to docetaxel alone or combined with the NF-kappaB inhibitor PS-1145 (an inhibitor of IkappaB kinase-2). Effects of dose, exposure time, and schedule dependence were assessed. Activation of NF-kappaB was assayed by electrophoresis mobility shift assay and luciferase reporter assay, IL-6 levels by ELISA, and cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell cycle and apoptosis were assessed by fluorescence-activated cell sorting analysis. Apoptosis was also measured by detection of cleavage of poly(ADP-ribose) polymerase. In patients with metastatic HIPC receiving docetaxel-based chemotherapy, IL-6 serum levels were assayed before chemotherapy and every 3 to 4 weeks thereafter., Results: PC-3 and DU-145 cells had higher NF-kappaB activity, secreted more IL-6, and were more resistant to docetaxel than LNCaP cells. NF-kappaB activity was induced by docetaxel. Cotreatment with docetaxel and PS-1145 prevented docetaxel-induced NF-kappaB activation, reduced IL-6 production, and increased docetaxel effects on cell viability in PC-3 and DU-145 cells but not in LNCaP. Synergism with docetaxel and PS-1145, as assayed by median-effect principle, was observed in DU-145 and PC-3. In HIPC patients, pretreatment IL-6 serum levels correlated to prostate-specific antigen (PSA) response: median IL-6 level was 10.8+/-9.5 pg/mL in PSA responders versus 36.7+/-20.8 pg/mL (P=0.006) in nonresponders. A PSA response was also linked to a decline in IL-6 levels during treatment. Median overall survival was 6.8 months in patients with high IL-6 versus 16.6 months in those with low IL-6 (P=0.0007). On multivariate analysis, pretreatment IL-6 (P=0.05) was an independent prognostic factor for time to disease progression and survival., Conclusions: Inhibition of NF-kappaB emerges as an attractive strategy to enhance docetaxel response in prostate cancer. The interest of this view is further supported by a significant association between high IL-6 in sera of HIPC patients and decreased response to docetaxel.
- Published
- 2006
- Full Text
- View/download PDF
207. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
- Author
-
Albanell J, Codony J, Rovira A, Mellado B, and Gascón P
- Subjects
- Antibodies, Monoclonal chemistry, Antibodies, Monoclonal, Humanized, Breast Neoplasms drug therapy, Breast Neoplasms immunology, Clinical Trials as Topic, Dimerization, Epitopes, Humans, Ligands, Models, Biological, Neovascularization, Pathologic, Protein Structure, Tertiary, Receptor, ErbB-2 chemistry, Signal Transduction, Trastuzumab, Antibodies, Monoclonal therapeutic use, Receptor, ErbB-2 antagonists & inhibitors
- Abstract
The HER family of transmembrane tyrosine kinase receptors is composed of four members, BER1 to HER4. HER2 is a ligand-orphan receptor expressed in many human tumors and overexpressed in 25-30% of breast cancers. HER2 amplifies the signal provided by other receptors of the HER family by forming heterodimers. The essential role of HER2 in the HER signaling network led to the development of anti-HER2 monoclonal antibodies (MAbs) for cancer therapy. In particular, the humanized MAb trastuzumab (Herceptin) has antitumor activity against HER2-overexpressing human breast tumor cells and is widely used for the treatment of women with HER2 overexpressing breast cancers. Trastuzumab induces HER2 receptor downmodulation and, as a result, inhibits critical signalling pathways (i.e. ras-Raf-MAPK and PI3K/Akt) and blocks cell cycle progression by inducing the formation of p27/Cdk2 complexes. Trastuzumab also inhibits HER2 cleavage, preceding antibody-induced receptor downmodulation, and this effect might contribute to its antitumor activity in some cancers. In vivo, trastuzumab inhibits angiogenesis and induces antibody-dependent cellular cytotoxicity. A limitation of trastuzumab is that its activity is largely restricted to breast cancers with the highest level of HER2 overexpression or HER2 gene amplification. However, there is a large population of breast cancers and of many other tumors that have low or moderate HER2 expression. In such tumors, HER2 functions as a preferred coreceptor to form heterodimers with HER1 (EGFR), HER3 or HER4. For this reason, a humanized monoclonal antibody, called 2C4, that targets the role of HER2 as a coreceptor is under active development. 2C4 binds to a different epitope of HER2 ectodomain than trastuzumab and sterically hinders HER2 recruitment in heterodimers with other HER receptors. This results in the inhibition of signalling by HER2-based heterodimers both in cells with low and high HER2 expression. In vitro and in vivo antitumor activity has been reported in a range of breast and prostate tumor models. Therefore, 2C4 may have potential against a wide variety of solid tumors. Phase I trials are underway.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.